01. Dementia/Alzheimer's disease
Target disease: Alzheimer's disease
At our company, the “Photo / ultrasonic response catalyst” discovered by Professor Motomu Kanai and Dr. Youhei Sohma of the University of Tokyo Graduate School of Pharmaceutical Sciences has been put into practical use as a drug for Alzheimer's disease using the technology of Professor Taisuke Tomita and Dr. Yukiko Hori.
This compound is a “Photo / ultrasonic response catalytic compound” that has an action mechanism of being activated by irradiation with light or ultrasonic waves, and this compound causes insoluble aggregate proteins (amyloid β, tau, α-synuclein) in the brain. Accelerates the decomposition of synuclein, etc.). Currently, Alzheimer's disease is a difficult disease to treat, but it can be applied as a novel modality treatment for various central nervous system diseases caused by other insoluble protein aggregation, which is characterized by insoluble protein aggregation.
By combining light and ultrasonic irradiation technology, it is possible to limit the activation site in the brain, and we are developing a new treatment method for central nervous system diseases using technology that enables irradiation in the brain.
02. Peripheral amyloidosis
Target disease: Cardiac / renal amyloidosis
We aim to treat peripheral amyloidosis using a light / ultrasonic response catalyst. Treatment of cardiac and renal AL amyloidosis, especially in multiple myeloma (MM patients), cardiac amyloidosis treatment by familial and acquired transthyretin (TTR) aggregation, peripheral amyloidosis by β2 microglobulin accumulation in renal dialysis patients.